NCT00910091已完成2 期
A Phase II International Multicentre Randomised Open Label Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Ipsen
- 入组人数
- 73
- 试验地点
- 54
- 主要终点
- Percentage of Women With Advanced or Recurrent Endometrial Cancer Who Have Neither Progressed Nor Died
研究概览
简要总结
This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.
详细描述
The Primary Objective in this study is to determine the antitumour efficacy of BN83495 measured by the percentage of women with advanced or recurrent endometrial cancer who have neither progressed nor died after 6 months of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Provision of written informed consent prior to any study related procedures
- •Post-menopausal or ovariectomised female patients over the age of 18 years with advanced or recurrent endometrial carcinoma
- •Histologically confirmed diagnosis endometrial carcinoma (primary tumour or metastasis)
- •Not eligible for surgery or radiotherapy alone, at Investigator's discretion
- •Documented Estrogen Receptor (ER) positivity in the primary tumour or in the metastatic tissue if the primary tumour is unavailable (ER positivity is defined by at least 10% positive cells)
- •No other history of malignant disease except treated basal cell or in situ cervical carcinoma in the previous 5 years. In case of previous malignant disease, pathological confirmation of metastatic endometrial cancer will be done at Investigator's discretion
- •Eastern Cooperative Oncology Group (ECOG) Performance status ≤2
- •At least one measurable disease site
- •minimum indicator lesion size: 20 mm (conventional techniques) or 10 mm (spiral CT scan)
- •target lesions not situated in irradiated area
- •Life expectancy ≥6 months
- •Adequate organ function as defined by the following criteria:
- •Haemoglobin ≥10 g/dL
- •Absolute neutrophil count (ANC) ≥1500/μL
- •Platelets ≥100,000/μL
- •Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥50 ml/min
- •Serum AST and serum ALT ≤2.5x ULN or AST and ALT ≤5x ULN if liver metastases
- •Total serum bilirubin ≤1.5x ULN
- •Serum albumin ≥3.0 g/dL
- •Cardiac function ≤New York Heart Association (NYHA) class II
- •Patients must have recovered from surgery, radiotherapy and toxicities of adjuvant chemotherapy treatment if applicable
- •Patients must be willing and able to participate in a clinical trial (including the completion of all necessary study procedures)
- •Patients must be able to swallow oral medication
排除标准
- •Use of any investigational agent in the 4 weeks prior to enrollment in this study
- •Prior systemic treatment for endometrial cancer (including hormonal treatment, chemotherapy, antiangiogenic or targeted therapies)with the exception of chemotherapy in the adjuvant setting, having been completed at least 6 months prior to randomisation
- •Known central nervous system (CNS) metastases
- •Ongoing cardiac dysrhythmias of National Cancer Institute Common Toxicity Criteria Adverse Events (NCI CTC AE) grade ≥2, atrial fibrillation of any grade, QTcF interval >460 msec.
- •Patients with contraindications to Megestrol Acetate (MA) including hypersensitivity to one of the drug product, any active arterial or venous thromboembolic event and/or uncontrolled hypertension. Patients receiving anticoagulation for a prior thromboembolic event may be enrolled in the study at the Investigator's discretion
- •Concomitant use of carbonic anhydrase II inhibitors (e.g. acetazolamide, dichlorphenamide, methazolamide)
- •History of hypersensitivity to BN83495 or drugs with a similar chemical structure
- •Likely to require treatment during the study with drugs that are not permitted by the study protocol
- •Abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study
研究组 & 干预措施
A- BN 83495- 40mg
Experimental
After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
干预措施: BN83495 (Drug)
B- MA - 160mg
Active Comparator
After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
干预措施: Megestrol Acetate (MA) (Drug)
结局指标
主要结局
Percentage of Women With Advanced or Recurrent Endometrial Cancer Who Have Neither Progressed Nor Died
时间窗: Up to 6 months
Subject continuation in the study and Response Evaluation Criteria in Solid Tumours (RECIST) assessment has been based on investigator assessment and not on central review. The 6 month timepoint is defined as the treatment start date +183 days (26 weeks).
次要结局
- Percentage of Participants With Adverse Event (AE)(Up to Day 28 follow-up)
- Tolerability of BN83495 Based on Length of Exposure(Up to 2 years)
- Tolerability of BN83495 Based on Cumulative Dose Administered(Up to 2 years)
- Tolerability of BN83495 Based on Dose Interruptions and Reason for Interruptions(Up to 2 years)
- Overall Survival (OS)(At 2 years)
- Progression Free Survival (PFS): Time From Randomisation Until Objective Tumour Progression or Death From Any Cause(Up to 2 years)
- Percentage of Participants >65 Years of Age With No Change or Deterioration, Improvement of <10%, or Improvement of ≥10% on the EuroQoL Score(Up to week 32)
- Percentage of Participants With Clinical Benefit [Including Completed Response (CR), Partial Response (PR), and Stable Disease (SD)] ≥12 Weeks(Up to 2 years)
- Percentage of Participants With Overall Response (OR) Including CR and PR(Up to 2 years)
- Percentage of Participants With First Documentation of Objective Tumour Progression From Randomisation(Up to 2 years)
- Duration of Response (DR) in Responders(At 2 years)
研究者
研究点 (54)
Loading locations...
相似试验
终止
3 期
Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer PatientsAnorexiaCachexiaWeight LossNCT00637728Par Pharmaceutical, Inc.5
终止
2 期
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for ChemotherapyAcute Myeloid LeukemiaNCT04150029Novartis Pharmaceuticals90
已完成
2 期
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major DepressionDepressionNCT01309945Bristol-Myers Squibb889
已完成
2 期
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major DepressionDepressionNCT01369095Bristol-Myers Squibb976
已完成
1 期
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 DiseaseBatten DiseaseJansky-Bielschowsky DiseaseLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2CLN2 DiseaseCLN2 DisorderNCT02485899BioMarin Pharmaceutical23